FDA Guidance on Medical Device Cybersecurity: A Crucial Step in Safeguarding Healthcare Technology

In an increasingly connected world, cybersecurity in healthcare technology has never been more critical. With medical devices becoming more integrated into hospital networks, clinical workflows, and patient care, their vulnerability to cyber threats has raised significant concerns. The FDA’s guidance on cybersecurity for medical devices offers essential guidelines to ensure the protection of these devices […]

Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry

Understanding the Guidance: What, Why, How In September 2025, the U.S. Food and Drug Administration (FDA) issued a nonbinding guidance for industry titled “Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.” U.S. Food and Drug Administration This document gives detailed recommendations for sponsors developing therapeutic protein biosimilars, especially how to design […]

FDA’s Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities: What It Means for Pharma

In September 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance document titled “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.” This guidance redefines how regulators and industry navigate facility assessments for pending drug applications—including NDAs, ANDAs, and BLAs. The new framework signals FDA’s intent to use more flexible, risk-based […]

Article: FDA Issues New Guidance on Animal Studies for Dental Bone Grafting Materials

Background & Purpose On August 22, 2025, the FDA released its latest guidance titled “Animal Studies for Dental Bone Grafting Material Devices – Premarket Notification (510(k)) Submissions,” building upon the original Dental Bone Grafting Guidance from 2005 U.S. Food and Drug Administration+1. The document offers nonbinding recommendations on conducting animal studies for dental bone grafting […]

Deep brief — Formal Meetings Between FDA and Sponsors/Applicants of BsUFA Products

Guidance for Industry (CDER & CBER, July 2025) — what it says, why it matters, and exactly what regulatory, pharmacovigilance (PV), quality, clinical and commercial teams must do day-to-day. U.S. Food and Drug Administration Quick summary (the headline) This FDA guidance codifies how sponsors of biosimilar or interchangeable biologic products should request, prepare for, run, […]

Stability testing of new drugs

Stability testing is to be performed to provide evidence on how the quality of a drug substance or formulation varies with time under the influence of various environmental factors such as temperature, humidity and light, and to establish shelf life for the formulation and recommended storage conditions. Stability studies should include testing of those attributes […]

error: Content is protected !!